US Patent

US9173851 — Delayed release cysteamine bead formulation, and methods of making and using same

Formulation · Assigned to Horizon Pharmaceutical LLC · Expires 2034-06-17 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a delayed release enteric-coated bead formulation of cysteamine bitartrate.

USPTO Abstract

An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.

Drugs covered by this patent

cysteamine-bitartrate (CYSTEAMINE BITARTRATE)

Patent Metadata

Patent number: US9173851
Jurisdiction: US
Classification: Formulation
Expires: 2034-06-17
Drug substance claim: No
Drug product claim: Yes
Assignee: Horizon Pharmaceutical LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.